A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Sep 2017 Results from EVOLVE-1 and EVOLVE-2 studies, presented at the 18th Congress of the International Headache Society 2017, according to The International Headache Society media release.
    • 06 Sep 2017 According to an Eli Lilly media release, data from this study will be presented at the 18th Congress of the International Headache Society (IHC) 2017.
    • 11 Jun 2017 Results of two phase III trials (NCT02614183 and NCT02614196) presented at the 59th Annual Scientific Meeting of the American Headache Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top